Literature DB >> 9815219

Enhancement of pulmonary clearance of Moraxella (Branhamella) catarrhalis following immunization with outer membrane protein CD in a mouse model.

T F Murphy1, J M Kyd, A John, C Kirkham, A W Cripps.   

Abstract

Moraxella (Branhamella) catarrhalis is an important human respiratory tract pathogen. Outer membrane protein (OMP) CD is highly conserved among strains and has characteristics that indicate it may be an effective vaccine antigen. This study investigated the effect of immunization with OMP CD on pulmonary clearance following intratracheal challenge of mice with M. catarrhalis. Two routes of immunization were studied: mucosal immunization (intra-Peyer's patch followed by intratracheal boost) and intramuscular immunization with OMP CD. Both resulted in enhanced pulmonary clearance of M. catarrhalis compared with sham-immunized controls. Immunization with OMP CD induced specific antibodies in serum and bronchoalveolar lavage fluid and induced a specific lymphocyte proliferative response in T cells from mesenteric lymph nodes from mice mucosally immunized with OMP CD. On the basis of these results, OMP CD should undergo continued testing to determine whether it will induce a protective immune response in humans.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9815219     DOI: 10.1086/314501

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  25 in total

1.  Analysis of antigenic structure and human immune response to outer membrane protein CD of Moraxella catarrhalis.

Authors:  T F Murphy; C Kirkham; E DeNardin; S Sethi
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

2.  Identification and characterization of a novel outer membrane protein (OMP J) of Moraxella catarrhalis that exists in two major forms.

Authors:  John P Hays; Saskia van Selm; Theo Hoogenboezem; Silvia Estevão; Kimberly Eadie; Peter van Veelen; Jan Tommassen; Alex van Belkum; Peter W M Hermans
Journal:  J Bacteriol       Date:  2005-12       Impact factor: 3.490

Review 3.  Potential impact of a Moraxella catarrhalis vaccine in COPD.

Authors:  Antonia C Perez; Timothy F Murphy
Journal:  Vaccine       Date:  2017-02-06       Impact factor: 3.641

4.  Epitope-specific immune recognition of the nontypeable Haemophilus influenzae outer membrane protein 26.

Authors:  Duangkamol Kunthalert; Laura A Novotny; Helen M Massa; Glen C Ulett; Lauren O Bakaletz; Jennelle M Kyd; Allan W Cripps
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

5.  Characterization of the Moraxella catarrhalis uspA1 and uspA2 genes and their encoded products.

Authors:  L D Cope; E R Lafontaine; C A Slaughter; C A Hasemann; C Aebi; F W Henderson; G H McCracken; E J Hansen
Journal:  J Bacteriol       Date:  1999-07       Impact factor: 3.490

Review 6.  Moraxella catarrhalis: from emerging to established pathogen.

Authors:  Cees M Verduin; Cees Hol; André Fleer; Hans van Dijk; Alex van Belkum
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

7.  Synthesis and characterization of lipooligosaccharide-based conjugate vaccines for serotype B Moraxella catarrhalis.

Authors:  Shengqing Yu; Xin-Xing Gu
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

8.  The Moraxella catarrhalis immunoglobulin D-binding protein MID has conserved sequences and is regulated by a mechanism corresponding to phase variation.

Authors:  Andrea Möllenkvist; Therése Nordström; Christer Halldén; Jens Jørgen Christensen; Arne Forsgren; Kristian Riesbeck
Journal:  J Bacteriol       Date:  2003-04       Impact factor: 3.490

Review 9.  A Moraxella catarrhalis vaccine to protect against otitis media and exacerbations of COPD: An update on current progress and challenges.

Authors:  Antonia C Perez; Timothy F Murphy
Journal:  Hum Vaccin Immunother       Date:  2017-10-03       Impact factor: 3.452

10.  Characterization of proteins Msp22 and Msp75 as vaccine antigens of Moraxella catarrhalis.

Authors:  Elizabeth A Ruckdeschel; Aimee L Brauer; Antoinette Johnson; Timothy F Murphy
Journal:  Vaccine       Date:  2009-09-26       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.